The story of an exceptional serine protease, tissue-type plasminogen activator (tPA).

Le 02 Nov 2021

Auteur : Hébert M, Lesept F, Vivien D, Macrez R

Année : 2016

Journal : Rev Neurol (Paris) 0035-3787

PubMed Id : 26626577

The only acute treatment of ischemic stroke approved by the health authorities is tissue recombinant plasminogen activator (tPA)-induced thrombolysis. Under physiological conditions, tPA, belonging to the serine protease family, is secreted by endothelial and brain cells (neurons, astrocytes, microglia, oligodendrocytes). Although revascularisation induced by tPA is beneficial during a stroke, research over the past 20 years shows that tPA can also be deleterious for the brain parenchyma. Thus, in this review of the literature, after a brief history on the discovery of tPA, we reviewed current knowledge of mechanisms by which tPA can influence brain function in physiological and pathological conditions.